Novyra Pharmachem FY26 Net Loss of ₹5.37 Crore

Board approved audited standalone financial results for FY26 ending March 31, 2026, reporting a net loss of ₹5.37 crore.
Company reported negative other equity of ₹5.71 crore and total assets of ₹1.46 crore against equity share capital of ₹6.30 crore.
Auditors D G M S & Co. LLP issued an unmodified opinion on the financial results, confirming compliance with SEBI LODR regulations.